2026-10-29T22:40:53Zhttps://bayburt-rdlopen.rawdatalibrary.net/oai/request

oai:bayburt-rdlopen.rawdatalibrary.net:bayburt/132892026-10-29T19:52:13Zopenairedrivercom_bayburt_10000col_bayburt_10001com_bayburt_10007col_bayburt_10225

Bio-catalytic asymmetric synthesis of β-adrenergic receptor blocker precursor: (R)-2-bromo-1-(naphthalen-2-yl)ethanolTaşdemir, VolkanKalay, ErbayDertli, EnesŞahin, Engin(R)-2-bromo-1-(naphthalen-2-yl)ethanolasymmetric reductionbiocatalystsChiral 2-haloethanolsLactobacillus curvatusAromatic α-halohydrins, particularly 2-haloethanols as significant precursor of drugs, can easily be converted to chiral β-adrenergic receptor blockers. Eight strains of Lactobacillus curvatus were tested as biocatalysts for asymmetric reduction of 2-bromo-1-(naphthalen-2-yl)ethanone 1 to 2-bromo-1- (naphthalen-2-yl) ethanol 2. The parameters of the bioreduction were optimized using L. curvatus N4, the best biocatalyst found. As a result, (R)-2-bromo-1-(naphthalen-2-yl)ethanol 2, which can be β-adrenergic receptor blocker precursor, was produced for the first time in high yield and enantiomerically pure form using biocatalysts. Moreover, the gram scale synthesis was performed and 7.54 g of (R)-2 was synthesized as enantiopure form (enantiomeric excess >99%) in 48 h. The important advantages of this process are that it produces of (R)-2 for the first time in enantiopure form, in excellent yield and under environmentally friendly and moderate reaction conditions. This system is of the potential to be applied at a commercial scale.Taylor and Francis Ltd.2020Articlehttps://rdlopen.rawdatalibrary.net/r/bayburt/13289https://doi.org/10.1080/10242422.2020.17682451024-2422enBiocatalysis and Biotransformationinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://bayburt-rdlopen.rawdatalibrary.net/tr/items/bayburt/13289